Skip to main content
MarketStoryBook

INCY in “America Imports the World's Drug Prices”

Incyte Corporation

Bear sideStableExposure: not rated yet

Incyte derives substantial value from patented products such as Jakafi and Opzelura, whose US pricing power could be constrained by foreign reference levels.

INCY impact map — “America Imports the World's Drug Prices”

How this story travels from the headline to INCY’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading INCY impact map…

Price history, marked with story events

Aug 31, 2026 – Sep 21, 2026 · 16 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

America Imports the World's Drug Prices

US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

BEAR side — Incyte derives substantial value from patented products such as Jakafi and Opzelura, whose US pricing power could be constrained by foreign reference levels.

Read the full America Imports the World's Drug Prices story

Bull side

1 story
  • The Patent Cliff Sparks a Biotech Land Grab

    INCY in “The Patent Cliff Sparks a Biotech Land Grab”

    FadingExposure: not rated yet

    Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

    Incyte's profitable oncology franchise and clinical pipeline provide strategic optionality for companies needing near-term revenue.

Bear side

1 story
  • INCY in “America Imports the World's Drug Prices”

    StableExposure: not rated yet
    Viewing

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Incyte derives substantial value from patented products such as Jakafi and Opzelura, whose US pricing power could be constrained by foreign reference levels.